In this episode, we dive into the future of e-health and pharmaceuticals. Kertti Merimaa from Nortal shares how AI is already transforming healthcare through diagnostics, clinical decision support, and predictive tools, while also dispelling common myths about AI in medicine. Jason Grenfell-Gardner, CEO of J. Molner Company, explains how Estonia became a base for pharmaceutical innovation and why fixing fragile drug supply chains is just as critical as breakthrough therapies.
All content for The Art of Digitalisation is the property of E-Estonia Briefing Centre and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, we dive into the future of e-health and pharmaceuticals. Kertti Merimaa from Nortal shares how AI is already transforming healthcare through diagnostics, clinical decision support, and predictive tools, while also dispelling common myths about AI in medicine. Jason Grenfell-Gardner, CEO of J. Molner Company, explains how Estonia became a base for pharmaceutical innovation and why fixing fragile drug supply chains is just as critical as breakthrough therapies.
In this episode, we dive into the future of e-health and pharmaceuticals. Kertti Merimaa from Nortal shares how AI is already transforming healthcare through diagnostics, clinical decision support, and predictive tools, while also dispelling common myths about AI in medicine. Jason Grenfell-Gardner, CEO of J. Molner Company, explains how Estonia became a base for pharmaceutical innovation and why fixing fragile drug supply chains is just as critical as breakthrough therapies.
The Art of Digitalisation
In this episode, we dive into the future of e-health and pharmaceuticals. Kertti Merimaa from Nortal shares how AI is already transforming healthcare through diagnostics, clinical decision support, and predictive tools, while also dispelling common myths about AI in medicine. Jason Grenfell-Gardner, CEO of J. Molner Company, explains how Estonia became a base for pharmaceutical innovation and why fixing fragile drug supply chains is just as critical as breakthrough therapies.
